tradingkey.logo
tradingkey.logo
Suchen

GSK plc

GSK
Zur Watchlist hinzufügen
52.500USD
+0.600+1.16%
Handelsschluss 06/26, 16:00ETKurse um 15 Minuten verzögert
105.93BMarktkapitalisierung
13.53KGV TTM

mehr Informationen über GSK plc Unternehmen

GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.

GSK plc Informationen

BörsenkürzelGSK
Name des UnternehmensGSK plc
IPO-datumMay 22, 1972
CEOWaterhouse (Deborah)
Anzahl der mitarbeiter68629
WertpapierartDepository Receipt
GeschäftsjahresendeMay 22
Addresse980 Great West Road
StadtBRENTFORD
BörseNASDAQ OMX NASDAQ Basic NYSE
LandUnited Kingdom
PostleitzahlTW8 9GS
Telefon442080475000
Websitehttps://www.gsk.com/
BörsenkürzelGSK
IPO-datumMay 22, 1972
CEOWaterhouse (Deborah)

Führungskräfte von GSK plc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Hal V. Barron, M.D.
Dr. Hal V. Barron, M.D.
Non-Executive Director
Non-Executive Director
602.23K
+0.01%
Ms. Shobie Ramakrishnan
Ms. Shobie Ramakrishnan
Chief Digital and Technology Officer
Chief Digital and Technology Officer
514.11K
+0.12%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
43.08K
+4.31%
Ms. Elizabeth McKee (Liz) Anderson
Ms. Elizabeth McKee (Liz) Anderson
Independent Non-Executive Director
Independent Non-Executive Director
4.24K
+18.60%
Dr. Jeannie Lee
Dr. Jeannie Lee
Independent Non-Executive Director and Scientific & Medical Expert
Independent Non-Executive Director and Scientific & Medical Expert
2.80K
+28.62%
Mr. David S. Redfern
Mr. David S. Redfern
President - Corporate Development
President - Corporate Development
--
--
Ms. Victoria Anne Whyte
Ms. Victoria Anne Whyte
Company Secretary
Company Secretary
--
--
Mr. Phil C. Thomson
Mr. Phil C. Thomson
President - Global Affairs
President - Global Affairs
--
--
Dame Emma N. Walmsley
Dame Emma N. Walmsley
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Luke Miels
Mr. Luke Miels
Chief Executive Officer - Designate, Director
Chief Executive Officer - Designate, Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Hal V. Barron, M.D.
Dr. Hal V. Barron, M.D.
Non-Executive Director
Non-Executive Director
602.23K
+0.01%
Ms. Shobie Ramakrishnan
Ms. Shobie Ramakrishnan
Chief Digital and Technology Officer
Chief Digital and Technology Officer
514.11K
+0.12%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
43.08K
+4.31%
Ms. Elizabeth McKee (Liz) Anderson
Ms. Elizabeth McKee (Liz) Anderson
Independent Non-Executive Director
Independent Non-Executive Director
4.24K
+18.60%
Dr. Jeannie Lee
Dr. Jeannie Lee
Independent Non-Executive Director and Scientific & Medical Expert
Independent Non-Executive Director and Scientific & Medical Expert
2.80K
+28.62%
Mr. David S. Redfern
Mr. David S. Redfern
President - Corporate Development
President - Corporate Development
--
--

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von GSK plc?

Die fünf größten Anteilseigner von GSK plc sind: Dr. Hal V. Barron, M.D.

Wie viele Institutionen halten Anteile an GSK plc (GSK)?

Mit Stand vom 2026Q1 halten 1585 Institutionen Anteile an GSK plc, mit einem Gesamtmarktwert von etwa 393.46M, was 19.40% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -23489904.00 gestiegen.

Was ist die größte Einnahmequelle von GSK plc?

Am 2026Q1 erzielte das Geschäft mit HIV für GSK plc den höchsten Umsatz in Höhe von 10.12B, was 23.53% des Gesamtumsatzes entspricht.
KeyAI